Total Payments
$415,382
2024 Payments
$27,157
Companies
6
Transactions
318
Payment Breakdown by Category
Consulting$162,357 (39.1%)
Travel$159,934 (38.5%)
Other$61,397 (14.8%)
Research$12,900 (3.1%)
Education$12,535 (3.0%)
Food & Beverage$6,259 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $162,357 | 60 | 39.1% |
| Travel and Lodging | $159,934 | 93 | 38.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $61,397 | 20 | 14.8% |
| Unspecified | $12,900 | 14 | 3.1% |
| Education | $12,535 | 24 | 3.0% |
| Food and Beverage | $6,259 | 107 | 1.5% |
Payments by Type
General
$402,482
304 transactions
Research
$12,900
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $173,626 | 123 | $0 (2024) |
| Shire North American Group Inc | $119,622 | 121 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $63,262 | 16 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $45,119 | 28 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $13,660 | 29 | $0 (2019) |
| Ultragenyx Pharmaceutical Inc. | $92.78 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27,157 | 10 | SANOFI-AVENTIS U.S. LLC ($20,944) |
| 2023 | $36,028 | 11 | SANOFI-AVENTIS U.S. LLC ($19,512) |
| 2022 | $30,295 | 12 | SANOFI-AVENTIS U.S. LLC ($22,807) |
| 2021 | $14,286 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($8,826) |
| 2020 | $21,252 | 15 | Takeda Pharmaceuticals U.S.A., Inc. ($11,335) |
| 2019 | $109,286 | 86 | GENZYME CORPORATION ($68,689) |
| 2018 | $109,408 | 99 | Shire North American Group Inc ($51,551) |
| 2017 | $67,670 | 79 | GENZYME CORPORATION ($34,437) |
All Payment Transactions
318 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ELAPRASE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,490.56 | General |
| Category: GENETIC DISEASE | ||||||
| 11/08/2024 | SANOFI-AVENTIS U.S. LLC | ALDURAZYME (Biological) | Travel and Lodging | In-kind items and services | $10,077.40 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | SANOFI-AVENTIS U.S. LLC | ALDURAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,769.00 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | SANOFI-AVENTIS U.S. LLC | ALDURAZYME (Biological) | Travel and Lodging | In-kind items and services | $645.31 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | SANOFI-AVENTIS U.S. LLC | ALDURAZYME (Biological) | Food and Beverage | In-kind items and services | $280.70 | General |
| Category: Genetic Disease | ||||||
| 11/08/2024 | SANOFI-AVENTIS U.S. LLC | ALDURAZYME (Biological) | Travel and Lodging | In-kind items and services | $171.22 | General |
| Category: Genetic Disease | ||||||
| 08/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ELAPRASE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,304.88 | General |
| Category: GENETIC DISEASE | ||||||
| 06/25/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,456.00 | General |
| 02/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ELAPRASE (Biological) | Consulting Fee | Cash or cash equivalent | $869.47 | General |
| Category: GENETIC DISEASE | ||||||
| 02/21/2024 | Ultragenyx Pharmaceutical Inc. | — | Food and Beverage | In-kind items and services | $92.78 | General |
| 10/20/2023 | SANOFI-AVENTIS U.S. LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $12,410.00 | General |
| 10/20/2023 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $6,137.91 | General |
| 10/20/2023 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $696.96 | General |
| 10/20/2023 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $218.84 | General |
| 10/20/2023 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $47.88 | General |
| 08/07/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ELAPRASE (Biological) | Consulting Fee | Cash or cash equivalent | $13,200.00 | General |
| Category: GENETIC DISEASE | ||||||
| 04/27/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $336.59 | Research |
| Study: A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID) | ||||||
| 04/27/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $250.00 | Research |
| Study: A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID) | ||||||
| 04/27/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $234.62 | Research |
| Study: A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID) | ||||||
| 03/24/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,461.00 | General |
| 02/21/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $1,033.78 | General |
| 11/04/2022 | SANOFI-AVENTIS U.S. LLC | ALDURAZYME (Biological) | Travel and Lodging | In-kind items and services | $14,072.20 | General |
| Category: Genetic Disease | ||||||
| 11/04/2022 | SANOFI-AVENTIS U.S. LLC | ALDURAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,193.00 | General |
| Category: Genetic Disease | ||||||
| 11/04/2022 | SANOFI-AVENTIS U.S. LLC | ALDURAZYME (Biological) | Travel and Lodging | In-kind items and services | $301.10 | General |
| Category: Genetic Disease | ||||||
| 11/04/2022 | SANOFI-AVENTIS U.S. LLC | ALDURAZYME (Biological) | Food and Beverage | In-kind items and services | $136.86 | General |
| Category: Genetic Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MPS-I Registry | GENZYME CORPORATION | $8,812 | 8 |
| Mucopolysaccharidosis I (MPS I) Registry | GENZYME CORPORATION | $3,267 | 3 |
| A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID) | Takeda Pharmaceuticals U.S.A., Inc. | $821.21 | 3 |
About Dr. Joseph Muenzer, MD
Dr. Joseph Muenzer, MD is a Pediatrics healthcare provider based in Chapel Hill, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306926944.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Muenzer, MD has received a total of $415,382 in payments from pharmaceutical and medical device companies, with $27,157 received in 2024. These payments were reported across 318 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($162,357).
Ad
Practice Information
- Specialty Pediatrics
- Location Chapel Hill, NC
- Active Since 10/17/2006
- Last Updated 03/30/2021
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1306926944
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $86,289
- ALDURAZYME (Drug) $66,748
- ELAPRASE (Biological) $66,427
- ALDURAZYME (Biological) $57,654
- Vimizim (Biological) $13,660
- ELAPRASE (Drug) $4,943
- DISEASE STATE (Drug) $45.00
- VPRIV (Biological) $13.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Chapel Hill
Dr. Michael Kappelman, Md, MD
Pediatrics — Payments: $92,929
Pediatrics $92,929
Maria Escolar
Pediatrics — Payments: $71,460
Pediatrics $71,460
David Peden, Md, MD
Pediatrics — Payments: $50,398
Pediatrics $50,398
Dr. Edwin Kim, M.d, M.D
Pediatrics — Payments: $29,015
Pediatrics $29,015
Steven Zeisel, Md, MD
Pediatrics — Payments: $24,726
Pediatrics $24,726
Dr. Thomas Ferkol, Md, MD
Pediatrics — Payments: $14,351
Pediatrics $14,351